Deadline: 11-Sep-2024
The MPN Heroes Recognition Program celebrates individuals and organizations committed to improving the lives of people impacted by the rare, chronic blood cancers called myeloproliferative neoplasms (MPNs).
The program was created in 2013 to foster the spirit of community. It focuses on the three “classical” MPNs—polycythemia vera (PV), essential thrombocythemia (ET), and myelofibrosis (MF).
The initiative honors patients, Healthcare Professionals, caregivers, advocates, and organizations. As MPN Heroes, they are recognized for their extraordinary efforts to bring understanding, compassion, and strength to the MPN community.
The MPN Heroes Recognition Program is sponsored by Incyte Corporation and CURE magazine. The goal of the program is to create as many opportunities as possible for people with MPNs to be heard and supported, so more solutions and treatment options will emerge.
Program Categories
- Category A: Commitment to the individual.
- Recognizing individuals who provide or demonstrate care, guidance, education, or support above and beyond the standard of care for one or more patients with MPNs.
- Types of work honored include demonstration of individual dedication by a nurse, Healthcare Professional, or caregiver whose contributions to an individual with an MPN had an evident impact.
- Category B: Commitment to the broader MPN community.
- Recognizing leadership in developing services or programs addressing the needs of patients with MPNs, families, friends, caregivers, and medical professionals through advancing the science and medical understanding of MPNs, education, awareness, or approaches to care.
- Types of work honored could include advocating for better care; outreach to underserved populations; activities at the grassroots level; promoting the patient’s voice; providing MPN community leadership; creating awareness programs, innovative education materials, programs, or events; disease management initiatives; research and science-based programs; media outreach; or campaigns.
Eligibility Criteria
- Criteria for nominations in either category are as follows:
- Choose only 1 category for the nominee to be considered
- Clearly state the MPN (MF, PV, ET) patient need being addressed
- The achievements of the organization or individual must be recent (ie, should have taken place within the last 24 months)
- Organizations may submit an entry for their own program, but it must be for 1 specific activity or program and only 1 entry per year, and they strongly encourage independent confirmation
- Individuals can be recognized posthumously
- Institutions, organizations, or individuals can be nominated by themselves or by others, but they must be aware of the nomination, and the nomination must be approved by, and compliant with, any institutional rules and guidelines
- Exclusions:
- Employees or agents of Incyte, Real Chemistry, or other Incyte vendors and members of their immediate family as well as current program year judging panel members are not eligible for recognition
- Nominated individuals, institutions, or organizations and the programs or activities nominated must originate and be executed in one or more of the 50 states of the United States, the District of Columbia, or Puerto Rico
- Nominated programs must be independent of purchase, use, and prescribing for any Incyte product
- Programs or activities that Incyte provided grants or other funding for directly
- Political lobbying activities
- Medical research or publications that have been funded or directed by Incyte
- Any nominee whose organization or institution does not allow recognition in the manner set forth in this program
- Nominated individuals or organizations must serve or be involved with the myelofibrosis (MF), polycythemia vera (PV), or essential thrombocythemia (ET) communities
- Judging panel reserves the right to exclude nominations of individuals for any perceived conflict of interest
- Individuals or organizations may not be recognized 2 years in a row or for a length of time agreed upon by the judging panel.
For more information, visit Incyte Corporation.
